Please login to the form below
HCC
This page shows the latest HCC news and features for those working in and with pharma, biotech and healthcare.
European Commission grants AstraZeneca three new approvals
The Imfinzi/ Imjudo approvals authorise the combination to be used for the first line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC), with the addition of platinum-based ... In HIMALAYA, the combination was
Latest news
-
Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer
HCC is a complex and heterogeneous tumour most commonly associated with chronic liver disease, especially hepatitis. ... combination reduced the risk of disease returning in people with this type of HCC.
-
Ipsen’s cabozantinib receives NICE approval for advanced hepatocellular carcinoma
Ipsen’s cabozantinib has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for patients with previously treated advanced hepatocellular carcinoma (HCC). ... HCC is the most common type of primary liver cancer
-
AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer
treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. ... HCC is a complex and heterogeneous tumour most commonly associated with underlying chronic liver disease, especially hepatitis.
-
Novartis and BeiGene announce positive phase 3 trial results for hepatocellular carcinoma treatment
Results from the phase 3 RATIONALE 301 trial of tislelizumab versus sorafenib as first-line treatment in patients with unresectable HCC were presented at a late-breaking session at the 2022 ... HCC is the most common type of liver cancer globally,
-
BeiGene announces positive phase 3 trial results for liver cancer treatment
HCC is the sixth most common type of cancer worldwide, the company reported, accounting for more than 900, 000 new cases in 2020. ... Despite improvements in screening, surveillance rules and imaging, more than two-thirds of patients with HCC present
More from news
Approximately 4 fully matching, plus 53 partially matching documents found.
Latest Intelligence
-
Mining for results
The first product to come from Apixio's technology platform is called the HCC Profiler.
-
Pharma Perspectives: The agency selection process (part 2)
Samuel Hollis is a business unit director at AstraZeneca. In Pharma Perspectives, published in association with the HCC, senior industry and agency figures address key marketing challenges. ... The Health Communications' Council (HCC) is a specialist
-
Pharma Perspectives: The agency selection process (part 1)
In Pharma Perspectives, published in association with the HCC, senior industry and agency figures address key marketing challenges. ... The Health Communications' Council (HCC) is a specialist division of the European Association of Communications
-
Pharma perspectives: communications creativity (part 2)
In the PME/PMLiVE series Pharma Perspectives with the HCC senior industry and agency figures give their thoughts on today's key marketing challenges. ... The Health Communications' Council (HCC) is a specialist division of the European Association of
-
Pharma perspectives: communications creativity (part 1)
In the PME/PMLiVE series Pharma Perspectives with the HCC senior industry and agency figures give their thoughts on today's key marketing challenges. ... The Health Communications' Council (HCC) is a specialist division of the European Association of
More from intelligence
Approximately 2 fully matching, plus 7 partially matching documents found.
Latest appointments
Consilium Strategic Communications appoints Chris Gardner
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
the body, including gastrointestinal (GI) tumors, pancreatic tumors, and hepatocellular carcinomas (HCC; the “VLA”). ... Oncologist. 2010; 15(suppl 4):42-52. Couri T, Pillai A. Goals and targets for personalized therapy for HCC.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
